Search Results - "Cabañas Poy, MJ"

NP-019 Development of a conversion factor between defined daily doses of adults and neonates by Villanueva Bueno, C, Gil Navarro, MV, Montecatine Alonso, E, Jiménez Parrilla, F, Cabañas Poy, MJ, González López, M, Martínez Fernández Llamazares, C, Neth, OW

“…Background and importanceAbsence of a standardised method to measure antimicrobial consumption in the neonatal populationAim and objectivesEstablish a…”
Get full text

4CPS-126 A population pharmacokinetic model of adalimumab in a cohort of paediatric patients with inflammatory bowel disease: a preliminary analysis by Miarons Font, M, Sánchez Hernandez, JG, Pérez Blanco, JS, Clemente Bautista, S, Rebollo Diaz, N, Segarra Cantón, O, Cabañas Poy, MJ, Torres Peral, R, Gorgas, MQ, Otero, MJ

“…Background and importanceTherapeutic drug monitoring is useful to optimise adalimumab therapy in patients with inflammatory bowel disease (IBD).Aim and…”
Get full text

5PSQ-138 Impact of high temperature, shaking and light on quality of the therapeutic peptide teduglutide (Revestive) evaluated by LC/MS/MS (Orbitrap) peptide mapping analysis and stress by Pérez-Robles, R, Navas, N, Clemente-Bautista, S, Jiménez-Lozano, I, Cabañas-Poy, MJ, Cabeza, J, Salmerón-García, A

“…Background and importance Teduglutide (Revestive) is a recombinant human GLP-2 analogue indicated in the treatment of short bowel syndrome, a serious and…”
Get full text

4CPS-242 Isavuconazole treatment in two paediatric patients during extracorporeal membrane oxygenation support: the role of therapeutic drug monitoring by Pau Parra, A, Pujol Jover, M, Melendo Pérez, S, Fernández-Polo, A, Miarons, M, Izquierdo Blasco, J, García-García, S, Ledesma, BFernández, Cabañas-Poy, MJ, Balcells, J, Clemente-Baustista, S

“…Background and ImportanceExtracorporeal membrane oxygenation (ECMO) may lead to pharmacokinetic alterations of antimicrobials. Isavuconazole is not approved in…”
Get full text

NP-012 Standardisation of analgesia and sedation infusion solutions in paediatric palliative patients receiving end-of-life care at home by Garcia-Palop B, B, Morgenstern Isaak, A, Cuso Cuquerella, C, Jimenez Lozano, I, Fernandez-Polo A, A, Cabanas Poy, MJ, Rodrigo Gonzalo de Liria, C, Gorgas Torner, MQ

“…BackgroundParenteral medication administration by continuous infusion has become a common practice in end-of-life home care settings because portable infusion…”
Get full text

4CPS-136 Analysis of the use of omalizumab in oral tolerance induction for high-risk food allergies in children by Larrosa García, M, Jimenez-Lozano, I, Blasco-Valero, C, Canete-Ramirez, C, Garriga-Baraut, MT, Garcia-Palop, BM, Vila-Indurain, BR, Clemente-Bautista, S, Cabanas-Poy, MJ

“…BackgroundOmalizumab-assisted oral-induced tolerance (oaOTI) has been proved to reduce the number of adverse events and shorten the time needed to reach…”
Get full text